In " Episode 6 " of the series on " Present and future of diagnostics in prostate cancer ", Assoc. Prof. Pawel Rajwa (PL) speaks with Prof. Peter Carroll (US) about the shifting landscape of active surveillance for intermediate-risk prostate cancer. Traditionally reserved for low-risk cases, active surveillance is now being considered for select patients with grade group 2 disease - especially when diagnosed through advanced techniques like MRI-targeted biopsy. Prof. Carroll explains how MRI has changed both the decision-making process and the biopsy approach, helping identify candidates with low risk of progression. The conversation addresses the potential to reduce overtreatment, minimise invasive follow-ups, and improve quality of life without compromising outcomes. Together, they examine how emerging data and imaging innovations are informing a more nuanced, patient-specific approach to prostate cancer care. For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts , Spotify , EAU YouTube channel .
